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Background: The mortality rate for renal artery bypass grafting (RABG) is reported to be 0% to 4% for patients with
renovascular hypertension and 4% to 7% for patients with ischemic nephropathy. However, these data come from
high-volume referral centers known for their expertise in treating these conditions. Because of the relative infrequency of
these operations in most vascular surgery practices, the nationwide outcomes for RABG are not known. The purpose of
this study was to define the operative mortality rate for RABG in the United States and to identify risk factors for
perioperative mortality.
Methods: The National Inpatient Sample was analyzed to identify patients undergoing RABG for the years 2000 to 2004.
Categoric data were analyzed using 2 and the Cochran-Armitage trend tests. Multivariate logistic regression analyses
were performed to identify risk factors for perioperative mortality after RABG.
Results: During the study period, 6608 patients underwent RABG, representing a frequency of 3.51 operations per
100,000 discharges. More than two-thirds were performed at teaching hospitals (4564 vs 2,044; P < .0001). The
frequency of RABG decreased by 30.7% between 2000 and 2004 (4.28 vs 2.96 RABGs per 100,000 discharges; P for
trend < .0001). The in-hospital mortality for RABG was 10.0%. On univariate analysis, in-hospital mortality after RABG
varied with increasing age, race, region of the country, and a preoperative history of chronic renal failure, congestive heart
failure, or chronic lung disease. Logistic regression models identified advanced age (odds ratio [OR] 1.57; 95% confidence
interval [CI], 1.44-1.72], female gender (OR, 1.20; 95% CI, 1.02-1.41), and a history of chronic renal failure (OR, 2.21;
95% CI, 1.75-2.78), congestive heart failure (OR, 1.94; 95% CI, 1.44-2.62), or chronic lung disease (OR, 1.40; 95% CI,
1.18-1.67) as independent markers of risk-adjusted, in-hospital mortality (P < .0001 for each of these five variables).
Conclusions: Nationwide in-hospital mortality after RABG is higher than predicted by prior reports from high-volume
referral centers. Advanced age, female gender, and a history of chronic renal failure, congestive heart failure, or chronic
lung disease were predictive of perioperative death. For the typical vascular practice, these data may provide a rationale for
lower risk alternatives, such as renal artery stenting or referral to high-volume referral centers for RABG. ( J Vasc Surg
2008;48:317-22.)For several decades, renal artery bypass grafting
(RABG) has been a mainstay of treatment for renovascular
hypertension (RVH) and ischemic nephropathy. Treat-
ment benefits have generally outweighed the operative risk
associated with these procedures. RABG has been associ-
ated with durable improvement or cure of hypertension in
82% of patients with RVH1-6 and with a salutary effect on
renal function in 43% to 80% of patients with ischemic
nephropathy.7-10 In published series, operative mortality
has ranged from 0% to 4.6% for RVH and 0% to 7.3% for
ischemic nephropathy.1-10 However, these mortality rates
may not reflect the national experience because they were
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doi:10.1016/j.jvs.2008.03.014reported by large referral centers with documented exper-
tise in the surgical treatment of renovascular disease. Fur-
thermore, the rapid increase in the number of percutaneous
interventions for renovascular disease in the past several
years has led to a drastic reduction in surgical RABG
volume.11 Because of the relative infrequency of RABG in
most vascular surgery practices today, the nationwide out-
comes for RABG are not known. The purpose of this study
was to define the operative mortality rate for RABG in the
United States and to identify predictors of perioperative
mortality.
MATERIAL AND METHODS
Database. The Nationwide Inpatient Sample (NIS)
from the Healthcare Cost and Utilization Project (HCUP)
was used to identify all patients undergoing RABG for the
years 2000 to 2004. This database represents the largest
all-payer inpatient database in the United States.12 The NIS
consists of a 20% stratified sampling of inpatient admissions
to US acute care hospitals. The database represents 1000
hospitals with 38 million discharges annually from a
variable number of states, ranging from 32 states in 2000 to
37 states in 2004. Patient demographics, primary and sec-
ondary diagnoses and procedures reported by Interna-
317
JOURNAL OF VASCULAR SURGERY
August 2008318 Modrall et altional Classification of Diseases, Ninth Revision, Clinical
Modification (ICD-9-CM) diagnosis and procedure codes,
and clinical outcomes are reported in the database. The
database lists 29 comorbidities defined by the HCUP (Ta-
ble I, on-line only) based on the presence of secondary
diagnoses after excluding postoperative complications and
diagnoses directly related to the primary diagnosis. To
generate national estimates of operation frequencies and
outcome events, both hospital and discharge weights are
provided, including data to calculate the variance of esti-
mates. The NIS databases are available to the public as
aggregate data without personal identifiers, making this
study exempt from review by the Institutional Review
Board.
Renal artery bypasses were identified using a combina-
tion of ICD-9-CM procedure and diagnosis codes. The
ICD-9-CM procedure codes for aortorenal bypass (39.24)
and “other abdominal bypass” (39.26) were merged with
the diagnosis codes for renal atherosclerosis (440.1) and
fibromuscular dysplasia (447.3) to identify patients under-
going RABG for these diagnoses. This strategy captured a
variety of open surgical RA reconstructions, including aor-
torenal bypass, hepatorenal bypass, splenorenal bypass, and
iliorenal bypass.
Comorbidities were itemized and used to calculate a
modified Charlson comorbidity index (CCI).13,14 The
CCI is a global measure of comorbidities that is calculated
for individual patients according to the presence of the four
atherosclerotic comorbidities of peripheral arterial disease,
myocardial infarction, cerebrovascular disease, and conges-
tive heart failure (CHF), and 13 nonatherosclerotic comor-
bid conditions, including diabetes mellitus with and with-
out complications, chronic lung disease, gastrointestinal
ulcer, arthritis, paraplegia, renal failure, malignancy with
and without metastasis, acquired immunodeficiency syn-
drome, dementia, liver disease, and liver failure.13,14 The
CCI has been validated for administrative databases and
correlated with operative morbidity andmortality for major
abdominal vascular operations, including RABG.13,15
Hospitals were classified as teaching or nonteaching
hospitals by the presence of any residency approved by the
Accreditation Council for Graduate Medical Education or
membership in the Council of Teaching Hospitals. Desig-
nation as an urban or rural hospital was according to 2000
Census definitions of urban population (50,000) or rural
population (50,000).16
Statistical analysis. The primary end point of the
study was in-hospital mortality after RABG. Categoric data
were analyzed using 2 and the Cochran-Armitage trend
tests. Continuous data were reported as medians and inter-
quartile ranges (IQR). Stepwisemultivariate logistic regres-
sion analyses were performed to identify predictors of peri-
operative death after RABG. The variables included in the
model were those with a P  .10 and other variables
hypothesized as being related to RABG mortality on theo-
retic grounds, as prescribed by Katz.17
The analyses were performed taking into account the
sampling design of the NIS. NIS stratum was used as thestratification variable. This variable is a four-digit stratum
identifier used to poststratify hospitals for the calculation of
universe and frame weights and contains information about
the NIS sampling strata. The PROC SURVEYFREQ and
PROC SURVEYLOGISTIC procedures of the SAS soft-
ware (SAS Inst, Cary, NC) were used to perform two-way
table and logistic regression analyses, respectively. To pro-
duce national estimates, all analyses were weighted using
the discharge-level weight variable provided in the NIS
dataset. For all statistical analyses, the threshold for signif-
icance was .05. Statistical analysis was performed using SAS
9.13 software.
RESULTS
During the study period (2000 to 2004), RABG pro-
cedures were performed on 6608 patients nationwide, in
whom 1.6% were performed for fibromuscular dysplasia
and atherosclerosis was the indication for operation in the
rest. In a subset of patients, the RABG was performed in
combination with open abdominal aortic aneurysm (AAA)
repair (0.6% of all RABGs), thoracoabdominal aortic aneu-
rysm (TAAA) repair (0.3% of all RABGs), or aortobifemoral
bypass (29.5% of all RABGs). RABG operations are relatively
rare, performed at a frequency of 3.51 operations per
100,000 discharges. The frequency of RABG decreased by
30.7% between 2000 and 2004 (P for trend  .0001).
The demographics and comorbid conditions of the
study population are outlined in Table II. The patient
population was typically male and white, with a median age
of 68 years (IRQ, 60-74 years). The extent of preoperative
comorbidity was scored using a modified CCI (Table II).
The median CCI was 1 (IQR, 1-2). The hospitals perform-
ing RABGs are characterized in Table III. More than
two-thirds of RABGs were performed at teaching hospitals,
even though teaching hospitals represented 17.4% of the
hospitals in theNIS database. Urban hospitals and hospitals
in the southern United States were disproportionately rep-
resented as sites for RABG.
The crude in-hospital mortality rate for RABG was
10.0% nationwide during the study period. Subset analysis
showed the mortality rate for RABG differed according to
the indication for surgery. No deaths occurred in 105
RABGs performed for fibromuscular dysplasia, but the
mortality rate was 10.1% (P  .0011) for those performed
for atherosclerosis. The in-hospital mortality rate was not
significantly different for RABG combined with AAA repair
(11.5%) or aortobifemoral bypass (9.9%) compared with
RABG alone (9.9%; P .95). The mortality rate for RABG
performed with TAAA repair was 0% (P  .27 vs RABG
alone), although only 20 cases were reported to the NIS
database during the 5-year study period.
On univariate analysis, mortality rates varied signifi-
cantly according to age, race, region of the country, and
primary expected payer (Table IV). Preoperative comor-
bidities, including chronic renal failure, CHF, and chronic
lung disease, had a substantial effect on in-hospital mortal-
ity (Table IV). Mortality also varied according to the CCI
(Table IV). Mortality was not affected significantly by sex,
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tion (urban vs rural), or the presence of obesity (Table IV).
To identify independent risk factors for in-hospital
mortality, 10 variables were entered into a stepwise logistic
regression model: age, sex, hospital teaching status (teach-
ing vs nonteaching), hospital region, hospital location (ur-
ban vs rural), primary expected payer, chronic renal failure,
Table II. Patient demographics and comorbidities
Characteristic Patients, No. (%) Pa
Sex .0001
Male 3494 (52.9)
Female 3114 (47.1)
Age, years .0001
1-17 73 (1.1)
18-44 266 (4.0)
45-64 2073 (31.4)
65-84 4039 (61.1)
85 104 (1.6)
Unknown age 52 (0.8)
Race .0001
White 4248 (64.3)
African American 289 (4.4)
Hispanic 141 (2.1)
Asian/Pacific Islander/other 177 (2.7)
Unknown 1754 (26.5)
Primary expected payer .0001
Medicare/Medicaid 4299 (65.4)
Private insurance 2094 (31.9)
Self-pay/other 183 (2.7)
Comorbidity
Congestive heart failure 327 (4.9)
Peripheral arterial disease 4089 (61.9)
Diabetes 801 (12.1)
Chronic pulmonary disease 1914 (29.0)
Chronic renal failure 598 (9.1)
Myocardial infarction 745 (11.3)
Cerebrovascular disease 139 (2.1)
Obesity 110 (1.7)
Charlson comorbidity index score .0001
0 1091 (16.5)
1 2575 (39.0)
2 1737 (26.3)
3 1205 (18.2)
a2 for equal proportions.
Table III. Hospital characteristics
Characteristic Percentage Pa
Hospital type .0001
Teaching 69.1
Nonteaching 30.9
Hospital location .0001
Urban 96.0
Rural 4.0
Hospital region .0001
South 42.8
Midwest 23.6
Northeast 22.0
West 11.6
a2 for equal proportions.CHF, chronic lung disease, and obesity. Multivariate anal-ysis identified age, female gender, chronic renal failure,
CHF, and chronic lung disease as independent predictors
of risk-adjusted in-hospital mortality (Table V). In fact, the
odds of in-hospital mortality were increased 57% for every
10-year increase in age. The presence of chronic renal
failure increased the risk of in-hospital mortality by 120%,
whereas CHF increased the mortality risk by 94%. Chronic
lung disease produced a 40% increase in the risk of in-
hospital mortality. Female gender had the least affect on
mortality among these variables, increasing the risk by 20%.
To assess the impact of the entire constellation of
Table IV. In-hospital mortality rates
Variable Mortality rate (%) Pa
Sex .13
Male 9.4
Female 10.6
Age, years .0001
1-17 0
18-44 3.6
45-64 6.5
65-84 12.0
85 24.6
Race .0001
White 10.2
African American 17.3
Hispanic 3.2
Asian/Pacific Islander/other 10.8
Hospital type .21
Teaching 9.7
Nonteaching 10.7
Hospital location .55
Urban 10.0
Rural 8.9
Hospital region .0001
South 9.5
Midwest 12.6
Northeast 9.6
West 7.0
Primary expected payer .0001
Medicare/Medicaid 12.1
Private insurance 6.2
Self-pay/other 5.8
Indication for surgery .0011b
Atherosclerosis 10.1
Fibromuscular dysplasia 0.0
Chronic renal failure .0001
Absent 9.2
Present 18.1
Congestive heart failure .0001
Absent 9.5
Present 18.5
Chronic lung disease .0003
Absent 9.1
Present 12.1
Obesity .37
Absent 9.9
Present 12.5
Charlson comorbidity index score .0001c
0 9.1
1 9.0
2 9.2
3 14.1
a2; bFisher’s Exact test; cCochran-Armitage trend test.comorbidities on mortality, a secondary stepwise logistic
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rather than with individual comorbidities. This model con-
firmed that age (odd ratio [OR], 1.57; 95% confidence
interval (CI), 1.44-1.72; P  .0001), female gender (OR,
1.20; 95% CI, 1.12-1.28; P .0001), and CCI (OR, 1.20;
95% CI, 1.02-1.41; P  .0001) were independent predic-
tors of in-hospital mortality. These data demonstrated that
operative mortality increased by 20% for every 1-point
increase in CCI.
DISCUSSION
RABG is a relatively rare operation. During the 5-year
study period (2000 to 2004), RABG was performed at a
frequency of 3.5 operations per 100,000 discharges. Our
data indicate that the frequency of RABGs has declined
30% from 2000 to 2004. A prior study from the University
of Michigan documented a 56% drop in RABG operations
between 1988 and 2001, coinciding with a 173% increase
in the frequency of catheter-based treatments of renovas-
cular disease.11 Whether this trend in the frequency of
RABG operations is a direct consequence of the prolifera-
tion of percutaneous RA stenting would be conjecture.
Nonetheless a potential consequence of this trend in the
frequency of RABG is the risk of diluting the experience
with RABG among individual surgeons and hospitals to
such an extent that it adversely impacts outcomes. To
address this question, we hypothesized that the nationwide
operative mortality rate for RABG is significantly higher
than previously reported by individual high-volume referral
centers. Indeed, using the largest all-payer inpatient data-
base in the United States, the NIS database, we found that
the crude in-hospital mortality rate for RABG was 10.0%
during the study period.
A 10% nationwide mortality rate for RABG stands in
stark contrast to those reported in single-center studies
published during the past several years. Several studies have
documented 30-day mortality rates of 0% to 4.6% for RVH
and 0% to 7.3% for ischemic nephropathy.1-10 In perhaps
the largest series of RA reconstructions reported to date,
the group at Wake Forest University reported a series of
626 patients undergoing RA reconstruction during a 13-
year period.1 Within this cohort, 397 patients underwent
RABG. Although the mortality rate for RABGs was not
reported separately, the 30-day mortality for the entire
cohort was 4.6%. Considering the burden of cardiovascular
disease in this subset of patients,18,19 this mortality rate is
Table V. Independent predictors of in-hospital mortality
Predictor
Odds ratio*
(95% Confidence interval) P Value
Age (per 10 year increase) 1.57 (1.44-1.71) P  .0001
Female gender 1.20 (1.02-1.42) P  .0001
Chronic renal failure 2.21 (1.75-2.78) P  .0001
Congestive heart failure 1.94 (1.44-2.62) P  .0001
Chronic lung disease 1.40 (1.18-1.67) P  .0001
*Odds ratio of in-hospital mortality after RA-bypass.laudable.It should be recognized, however, that this mortality
rate is the product of a high-volume referral center that
performed a minimum of 30 RABG operations per year
from 1987 to 1999. Our data on the nationwide frequency
of RABG operations (3.5 operations per 100,000 dis-
charges) suggest that RABGs are rare operations in most
vascular practices. Given this disparity in the frequency of
RABG operations between practices, it is perhaps not sur-
prising that nationwidemortality rates for RABG are higher
than those reported by centers that frequently perform
these operations.
The gap inmortality rates between large referral centers
and nationwide data is recapitulated for patients operated
on for presumed ischemic nephropathy. Hansen et al7 from
Wake Forest University reported a series of 232 patients
undergoing renal revascularization for ischemic nephropa-
thy during an 11-year period.7 Two-thirds of patients un-
derwent RABG, but this subset was not analyzed apart from
the larger study population. The operative mortality rate
for the entire cohort was 7.3%. Marone and the Massachu-
setts General Hospital group reported a series of 96 patients
with ischemic nephropathy,8 of whom 76% underwent
RABG. Again, the RABG procedures were not analyzed
separately, but the overall mortality was 4.1%. The current
study, in contrast, found that patients with chronic renal
failure had an in-hospital mortality rate of 18.1%, whereas
patients without renal failure had a 9.2% mortality rate
(Table IV). These data demonstrate once again that the
nationwide mortality rates are more than twofold higher
than those reported by high-volume referral centers.
An additional goal of this study was to define the
variables that may increase the risk of in-hospital mortality
for RABG surgery. Our data analyses identified advanced
age, female gender, chronic renal failure, CHF, and chronic
lung disease as independent predictors of in-hospital mor-
tality after RABG (Table V). These data reinforce prior
studies that identified advanced age, chronic renal failure,
and CHF as risk factors for operative mortality after
RABG.1,7 Although chronic lung disease had not been
previously associated with an increased risk of death after
RABG, it has been associated with increased mortality for
AAA repair.20 It is not clear why women are predisposed to
a higher risk of in-hospital mortality after RABG. This
finding deserves further investigation.
The mortality data reported in the current study are
sobering. A central question raised by these data is: What
distinguishes centers with acceptably lowmortality rates for
RABG from other centers? We hypothesize that improved
results reported in single-center studies are related to the
volume of RABG operations performed in those centers. It
is likely that both surgeons and ancillary personnel in these
centers develop experience and expertise in patient selec-
tion, operative management, and perioperative care that
translates into improved outcomes. The concept of volume-
related improvements in outcomes has received significant
attention in recent years. Using large administrative data-
bases, several groups have documented that outcomes for
carotid endarterectomy and AAA repair are related to hos-
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surmise that RABG is another example of this phenome-
non, although further investigation is required to address
this hypothesis.
The implications of this study for clinical practice are
significant. First, an operative mortality rate of 10% for
RABG casts an unflattering light on an operation with
documented ability to improve long-term survival among
patients with a favorable response of blood pressure or renal
function.1,7 Factoring these data into the risk-benefit anal-
ysis for RABG may mitigate against surgical revasculariza-
tion in many patients. In an era of unprecedented scrutiny
by federal agencies, third-party payers, and the public sec-
tor, it is incumbent upon surgeons to heed these unfavor-
able results and collectively strive to improve outcomes. It
would be reasonable, for instance, for surgeons and hospi-
tals to prospectively monitor outcomes for RABG analo-
gous to other surgical quality-improvement initiatives, such
as the National Veterans Administration Surgical Quality
Improvement Program and the Northern New England
Cardiovascular Disease Study Group, that have improved
surgical outcomes.27,28
These data also have profound implications on patient
selection for RABG. We identified five predictors of a
higher risk of in-hospital mortality after RABG: advanced
age, female gender, and preoperative chronic renal failure,
CHF, or chronic lung disease. The presence of multiple
predictors in a given patient may warrant consideration of
lower-risk alternatives, including medical therapy, extra-
anatomic bypass, or RA stenting. Despite the potential
benefits of renal revascularization in survivors, high opera-
tive mortality rates for RABGmay strengthen the argument
for medical management rather than surgery in patients
with RVH or ischemic nephropathy. Several studies have
documented a lower risk of operative mortality for hepato-
renal and splenorenal bypasses, making this an attractive
surgical option in some patients.2,29,30 Percutaneous RA
stenting offers the obvious advantages a lower risk of mor-
bidity andmortality andmore rapid return to full functional
status compared with surgery. Unfortunately, percutane-
ous renal revascularization has also yielded less favorable
outcomes for blood pressure and renal function.31,32 Fi-
nally, for surgeons who do not perform RABG regularly,
these data may provide a rationale for referral to high-
volume centers with documented expertise and acceptable
outcomes for RABG.
The current study has some limitations that deserve
comment. First, the use of administrative databases for
population-based outcome studies has been criticized by
some authors.33,34 These investigators contend that data
derived from administrative databases may be contami-
nated by inaccurate coding, undercoding of comorbidities,
nonstandardized mortality end points, and use of the data
for analyses for which they were not intended. These au-
thors have proposed the use of clinical databases that have
extensively been audited for accuracy, rather than adminis-
trative databases. The shortcoming of this approach lies in
the relative lack of statistical power provided by the smallvolume of RABG operations performed in each center.
Moreover, the largest clinical databases would be derived
from high-volume referral centers with expertise particular
expertise in treating renovascular disease, which may intro-
duce another source of bias.
Concerns about the end point of the study, in-hospital
mortality, are valid because in-hospital mortality is not
necessarily equivalent to 30-daymortality. This discrepancy
may actually underestimate the true 30-day mortality rate
for RABG, which would not alter the conclusions of the
current study. In addition, it is beyond the scope of this
study to assess the impact of extra-anatomic bypasses on
mortality for RABG.
Perhaps the most significant shortcoming of these data
is the inability to pinpoint what distinguishes centers with
acceptably low mortality rates for RABG from other cen-
ters. Future studies will need to address this issue.
A final issue relates to the true mortality rate in centers
that do not regularly perform RABG operations. Because a
disproportionate volume of RABGs are performed by a few
centers, it is possible that the excellent results from these
centers actually lower the nationwide mortality rate. This
logic would suggest that the mortality rate for other centers
is actually higher than 10%, which would pose an even
greater concern.
CONCLUSIONS
The current study found that nationwide in-hospital
mortality after RABG is significantly higher than predicted
by prior reports from individual high-volume referral cen-
ters. Several predictors of operative mortality were identi-
fied that may assist with patient selection for RABG. For
surgeons who do not regularly perform RABG operations,
these data may provide a rationale for lower-risk alterna-
tives, such as RA stenting, or referral to high-volume cen-
ters for RABG.
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Healthcare Cost and Utilization Project
Comorbidity
Acquired immune deficiency syndrome
Alcohol abuse
Deficiency anemias
Rheumatoid arthritis/collagen vascular diseases
Chronic blood loss anemia
Congestive heart failure
Chronic pulmonary disease
Coagulopathy
Depression
Diabetes, uncomplicated
Diabetes with chronic complications
Drug abuse
Hypertension
Hypothyroidism
Liver disease
Lymphoma
Fluid and electrolyte disorders
Metastatic cancer
Other neurologic disorders
Obesity
Paralysis
Peripheral vascular disorders
Psychoses
Pulmonary circulation disorders
Renal failure
Solid tumor without metastasis
Peptic ulcer, excluding bleeding
Valvular heart disease
Weight loss
